EUVIMEDEUVIMED entdecken
Crossref

Differential frequency of persister cells in clinically derived isolates of Pseudomonas aeruginosa after exposure to cefiderocol and ceftolozane/tazobactam

Aliaa Fouad, Samantha E Nicolau, Pranita D Tamma iD, Patricia J Simner, David P Nicolau, Christian M Gill iD

Journal of Antimicrobial Chemotherapy · 02.12.2024 · 79 (12) · 3236-3242

DOI: 10.1093/jac/dkae346 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 24.10.2024. Verfasst von Aliaa Fouad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Cephalosporins, Tazobactam, Anti-Bacterial Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Shionogi & Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bacterial persistence is a phenomenon whereby a subpopulation of bacteria survive high concentrations of an active antibiotic in the absence of phenotypic alterations. Persisters are associated with chronic and recurrent infections for pathogens including Pseudomonas aeruginosa. Understanding persister profiles of newer antibiotics such as cefiderocol and ceftolozane/tazobactam against P. aeruginosa is warranted as these agents generally target difficult-to-treat infections.

Methods

Persister formation was assessed using in vitro assays against nine clinical P. aeruginosa isolates exposed to cefiderocol or ceftolozane/tazobactam. Quantitative persister assays were performed using a stationary phase of bacteria challenged with 10-fold MIC drug concentrations. Persisters were quantitated as the percent persisters at 24 h and the log ratio (LR) difference in AUC for cfu for each antibiotic alone compared with growth control. The tolerance disc test (TDtest) was used to qualitatively detect persisters.

Results

Percent persisters at 24 h was lower with cefiderocol compared with ceftolozane/tazobactam for six of the nine tested isolates. Eight of the nine isolates had higher reduction in LR for cefiderocol groups, suggesting an overall higher and more rapid bacterial reduction in cefiderocol groups. For cefiderocol, five of the nine tested isolates lacked regrowth after replacement with glucose disc, suggesting no persistence via the TDtest. For ceftolozane/tazobactam, three isolates lacked persister formation.

Conclusions

Cefiderocol resulted in less bacterial persistence relative to ceftolozane/tazobactam against nine clinical P. aeruginosa isolates. Cefiderocol’s siderophore mechanism may be advantageous over ceftolozane/tazobactam through enhanced anti-persister effects. Clinical correlation of these findings is warranted as persisters can lead to antibiotic resistance and treatment failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaCephalosporinsTazobactamAnti-Bacterial AgentsMicrobial Sensitivity TestsPseudomonas InfectionsCefiderocolHumansPenicillanic AcidMicrobial Viability

Substanzen

CephalosporinsTazobactamAnti-Bacterial Agentsceftolozane, tazobactam drug combinationCefiderocolPenicillanic Acid

Autor:innen und Institutionen

  • Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.
  • mRNA Center of Excellence, Sanofi Pasteur, Waltham, MA, USA.
  • Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Division of Infectious Diseases, Hartford Hospital, Hartford, CT, USA.

ORCID-Profile: Pranita D Tamma, Christian M Gill

Förderung

  • Shionogi & Co., Ltd

Zitieren

APA

Fouad, A., Nicolau, S. E., Tamma, P. D., Simner, P. J., Nicolau, D. P., & Gill, C. M. (2024). Differential frequency of persister cells in clinically derived isolates of Pseudomonas aeruginosa after exposure to cefiderocol and ceftolozane/tazobactam. Journal of Antimicrobial Chemotherapy, 79(12), 3236-3242. https://doi.org/10.1093/jac/dkae346

Vancouver

Fouad A, Nicolau SE, Tamma PD, Simner PJ, Nicolau DP, Gill CM. Differential frequency of persister cells in clinically derived isolates of Pseudomonas aeruginosa after exposure to cefiderocol and ceftolozane/tazobactam. Journal of Antimicrobial Chemotherapy. 2024;79(12):3236-3242. doi:10.1093/jac/dkae346

BibTeX
@article{Fouad2024,
  author = {Fouad, Aliaa and Nicolau, Samantha E and Tamma, Pranita D and Simner, Patricia J and Nicolau, David P and Gill, Christian M},
  title = {Differential frequency of persister cells in clinically derived isolates of Pseudomonas aeruginosa after exposure to cefiderocol and ceftolozane/tazobactam},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {12},
  pages = {3236--3242},
  doi = {10.1093/jac/dkae346}
}
Kostenlos starten →